Search

Studies the effect of rapamycin on platelets in vivo and in vitro. Utilization of flow cytometry; Increase of in vitro resting platelet degranulation; Effect of splenic sequestration of activated platelets.

Objectives: The Massachusetts Veterans Epidemiology Research and Information Center in collaboration with the Stanford Center for Innovative Study Design set out to test the feasibility of a new method of evidence generation. The first pilot of a point-of-care clinical trial (POCCT), adding randomization and other study processes to an electronic medical record (EMR) system, was launched to compare the effectiveness of two insulin regimens.Materials and Methods: Existing functionalities of the Veterans Affairs (VA) computerized patient record system (CPRS)/veterans health information systems and technology architecture (VISTA) were modified to support the activities of a randomized controlled trial including enrolment, randomization, and longitudinal data collection.Results: The VA's CPRS/VISTA was successfully adapted to support the processes of a clinical trial and longitudinal study data are being collected from the medical record automatically. As of 30 June 2011, 55 of the 67 eligible patients approached received a randomized intervention.Discussion: The design of CPRS/VISTA made integration of study workflows and data collection possible. Institutions and investigators considering similar designs must carefully map clinical workflows and clinical trial workflows to EMR capabilities. POCCT study teams are necessarily interdisciplinary and interdepartmental. As a result, executive sponsorship is critical.Conclusion: POCCT represent a promising new method for conducting clinical science. Much work is needed to understand better the optimal uses and designs for this new approach. Next steps include focus groups to measure patient and clinician perceptions, multisite deployment of the current pilot, and implementation of additional studies. [ABSTRACT FROM AUTHOR]

Presents a study on the capability of calcineurin channel inhibitors to stimulate platelet degranulation and fibrinogen binding in a dose-dependent manner. Evaluation of the impact of various dosages of cyclosporin A and tacrolimus; Determination of the expression of P-selectin; Involvement of the inhibitors in the pathogenesis of chronic allograft nephropathy.